Expression profiling of human idiopathic dilated cardiomyopathyRafal Grzeskowiak, Rainer Spang, Henning Witt et al.|Cardiovascular Research|2003Cited by 93
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognosticationDavid Miles, Hamdy Abdel Azeem, Eva Ciruelos et al.|Annals of Oncology|2021Cited by 92
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08)Roger von Moos, Kathrin Zaugg, Dieter Koeberle et al.|European Journal of Cancer|2017Cited by 27
<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancerPhilip D. Dunne, Mark Lawler, Ronan T. Gray et al.|Oncotarget|2018Cited by 11
Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients (pts) with locally advanced, k-ras-mutated rectal cancer (LARC): A phase I/II trial SAKK 41/08.Roger von Moos, Kathrin Zaugg, Dieter Koeberle et al.|Journal of Clinical Oncology|2014Cited by 5